Premium
Cell transfer‐based immunotherapies in cancer: A review
Author(s) -
Gorabi Armita M.,
Hajighasemi Saeideh,
Sathyapalan Thozhukat,
Sahebkar Amirhossein
Publication year - 2020
Publication title -
iubmb life
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.132
H-Index - 113
eISSN - 1521-6551
pISSN - 1521-6543
DOI - 10.1002/iub.2180
Subject(s) - immune system , adoptive cell transfer , immunology , immunotherapy , cancer research , cancer , medicine , dendritic cell , cancer cell , t cell
In cell transfer therapy (CTT), immune cells such as innate immune‐derived natural killer cells and dendritic cells as well as acquired immune‐related T lymphocytes such as tumor‐infiltrating lymphocytes and cytokine‐activated or genetically modified peripheral blood T cells are used in the management of cancer. These therapies are increasingly becoming the most used treatment modality in cancer after tumor resection, chemotherapy, and radiotherapy. In adoptive cell transfer, the lymphocytes isolated from either a donor or the patient are modified ex vivo and reinfused to target malignant cells. Transferring in vitro‐manipulated immune cells produces a continuous antitumor immune response. In this review, we evaluate the recent advances in CTT for the management of various malignancies.